Pharming reports revenue growth and strategic expansion in 2024

13 March 2025

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 million, surpassing its guidance.

The company’s revenue growth was driven by strong sales of its flagship drug Ruconest (conestat alfa) and significant growth in Joenja (leniolisib) sales.

In the fourth quarter, revenue rose 14% year-on-year to $93 million, with operating profit increasing to $6.7 million from $1.1 million in the same period in 2023. However, the company posted a full-year net loss of $11 million, slightly higher than the $10.5 million loss recorded in 2023. Earnings per share for the year remained unchanged at a loss of $0.016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK